Equities analysts predict that Recro Pharma Inc (NASDAQ:REPH) will report earnings per share of ($0.67) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Recro Pharma’s earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.91). Recro Pharma posted earnings per share of ($0.48) during the same quarter last year, which would indicate a negative year over year growth rate of 39.6%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 8th.
On average, analysts expect that Recro Pharma will report full-year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.33). For the next fiscal year, analysts expect that the firm will report earnings of ($2.48) per share, with EPS estimates ranging from ($4.21) to ($0.10). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last released its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.34) by $0.72. The company had revenue of $21.74 million during the quarter, compared to analyst estimates of $16.81 million. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%.
A number of analysts have recently issued reports on REPH shares. Oppenheimer set a $18.00 target price on Recro Pharma and gave the company a “buy” rating in a report on Wednesday, August 8th. ValuEngine upgraded Recro Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 4th. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, May 31st. Janney Montgomery Scott dropped their price target on shares of Recro Pharma from $21.00 to $11.00 and set a “fair value” rating on the stock in a research note on Thursday, May 24th. Finally, Roth Capital set a $9.00 price target on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Saturday, May 26th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $12.63.
REPH opened at $8.56 on Friday. The firm has a market capitalization of $172.37 million, a PE ratio of -4.30 and a beta of -0.81. Recro Pharma has a 12-month low of $4.78 and a 12-month high of $13.05. The company has a quick ratio of 1.42, a current ratio of 1.59 and a debt-to-equity ratio of 2.22.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Recro Pharma by 27.6% in the second quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock worth $5,747,000 after acquiring an additional 247,559 shares during the last quarter. Lyon Street Capital LLC increased its position in Recro Pharma by 182.6% during the first quarter. Lyon Street Capital LLC now owns 1,027,271 shares of the specialty pharmaceutical company’s stock worth $11,310,000 after buying an additional 663,776 shares during the last quarter. Newtyn Management LLC acquired a new position in Recro Pharma during the second quarter worth $4,456,000. Engine Capital Management LP increased its position in Recro Pharma by 472.3% during the second quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock worth $1,964,000 after buying an additional 322,937 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Recro Pharma by 5.2% during the second quarter. Renaissance Technologies LLC now owns 381,300 shares of the specialty pharmaceutical company’s stock worth $1,914,000 after buying an additional 18,700 shares during the last quarter. 55.86% of the stock is currently owned by institutional investors and hedge funds.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
See Also: Average Daily Trade Volume Explained
Get a free copy of the Zacks research report on Recro Pharma (REPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.